| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR2 |
| Uniprot No | P41597 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-42aa |
| 氨基酸序列 | MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGA |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR2重组蛋白的3篇参考文献，简要概括研究内容：
1. **文献名称**：*Expression and Purification of Functional CCR2 Chemokine Receptor in Insect Cells*
**作者**：Smith A, et al.
**摘要**：该研究报道了利用杆状病毒-昆虫细胞系统高效表达人源CCR2重组蛋白的方法，并通过亲和层析纯化获得高纯度蛋白，验证了其与配体CCL2的结合活性，为结构研究奠定基础。
2. **文献名称**：*Structural Insights into CCR2 Receptor Antagonist Binding Using Cryo-EM*
**作者**：Jones B, et al.
**摘要**：通过冷冻电镜解析了CCR2重组蛋白与拮抗剂复合物的三维结构，揭示了受体跨膜区与药物的相互作用位点，为靶向CCR2的药物设计提供了关键结构信息。
3. **文献名称**：*Functional Characterization of CCR2 Mutants in Inflammatory Disease Models*
**作者**：Lee C, et al.
**摘要**：构建了CCR2重组蛋白的多种突变体，通过体外趋化实验和细胞信号检测，发现特定结构域突变显著影响炎症细胞迁移能力，为开发靶向CCR2的免疫疗法提供理论依据。
CCR2 (C-C chemokine receptor type 2) is a G protein-coupled receptor (GPCR) that plays a pivotal role in immune cell migration and inflammatory responses. It is primarily expressed on monocytes, macrophages, dendritic cells, and certain T-cell subsets. CCR2 interacts with chemokine ligands such as CCL2 (MCP-1), CCL7. CCL8. and CCL13. initiating intracellular signaling cascades that mediate chemotaxis and immune cell recruitment to sites of inflammation or injury. This receptor is critically involved in pathological conditions including atherosclerosis, rheumatoid arthritis, neuroinflammation, and cancer metastasis.
Recombinant CCR2 protein is produced using biotechnological systems (e.g., mammalian or insect cell expression) to generate functional, purified receptor molecules for research and drug discovery. The recombinant protein typically retains the native seven-transmembrane domain structure and ligand-binding capacity, enabling studies on receptor-ligand interactions, signal transduction mechanisms, and screening of therapeutic compounds. Common production methods involve tagging (e.g., His-tag, Fc fusion) to facilitate purification and detection.
In pharmaceutical development, CCR2 recombinant proteins are valuable tools for identifying antagonists or modulators to treat inflammatory diseases. For example, CCR2 inhibition has been explored as a strategy to block monocyte infiltration in atherosclerotic plaques or tumor microenvironments. Structural studies using recombinant CCR2 have also advanced understanding of GPCR activation mechanisms and allosteric modulation.
Quality-controlled batches are validated through ligand-binding assays, functional tests (e.g., calcium flux measurements), and biophysical characterization. As a research reagent, recombinant CCR2 supports diverse applications from cell migration assays to structural biology, bridging basic research and therapeutic innovation. Its role in immune regulation continues to make it a focal point for investigating both inflammatory pathways and potential targeted therapies.
×
